275 related articles for article (PubMed ID: 31186405)
1. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
Zhang X; Hu B; Sun YF; Huang XW; Cheng JW; Huang A; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J; Yang XR
Clin Transl Med; 2021 Feb; 11(2):e335. PubMed ID: 33634982
[TBL] [Abstract][Full Text] [Related]
3. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
4. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
Wang GZ; Zhang W; Fang ZT; Zhang W; Yang MJ; Yang GW; Li S; Zhu L; Wang LL; Zhang WS; Liu R; Qian S; Wang JH; Qu XD
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1125-36. PubMed ID: 24756364
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1.
Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P
Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Zhang KZ; Zhang QB; Zhang QB; Sun HC; Ao JY; Chai ZT; Zhu XD; Lu L; Zhang YY; Bu Y; Kong LQ; Tang ZY
J Hematol Oncol; 2014 Mar; 7():28. PubMed ID: 24678763
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.
Qiu Y; Dai Y; Zhang C; Yang Y; Jin M; Shan W; Shen J; Lu M; Tang Z; Ju L; Wang Y; Jiao R; Xia Y; Huang G; Yang L; Li Y; Zhang J; Wong VKW; Jiang Z
J Exp Clin Cancer Res; 2018 Dec; 37(1):321. PubMed ID: 30572915
[TBL] [Abstract][Full Text] [Related]
10. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma.
Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X
Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794
[TBL] [Abstract][Full Text] [Related]
11. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
12. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma.
Qu K; Wang Z; Fan H; Li J; Liu J; Li P; Liang Z; An H; Jiang Y; Lin Q; Dong X; Liu P; Liu C
Cell Death Dis; 2017 Feb; 8(2):e2603. PubMed ID: 28182015
[TBL] [Abstract][Full Text] [Related]
13. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F
Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952
[TBL] [Abstract][Full Text] [Related]
14. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
15. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G
Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo.
Zhao XS; Song PL; Sun B; Jiang HC; Liu TF
Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):510-7. PubMed ID: 19822495
[TBL] [Abstract][Full Text] [Related]
18. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
[TBL] [Abstract][Full Text] [Related]
20. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]